Related Experiment Video
Updated: Jun 2, 2026
06:31
Transuterine Fetal Tracheal Occlusion Model in Mice
Published on: February 5, 2021
Risk Stratification and Fetal Therapies for Congenital Diaphragmatic Hernia
Connor V Haynes1,2, David H Stitelman1
1Yale New Haven Children's Hospital, Division of Pediatric Surgery, New Haven, Connecticut.
Neoreviews
|May 31, 2026
Summary
Congenital diaphragmatic hernia (CDH) is a complex condition where fetal therapies like tracheal occlusion show promise. These interventions aim to improve survival by addressing prenatal lung development issues before birth.
Area of Science:
- Pediatric Surgery
- Neonatology
- Fetal Medicine
Background:
- Congenital diaphragmatic hernia (CDH) presents significant challenges in neonates, with outcomes determined prenatally.
- Pulmonary hypoplasia and hypertension are key drivers of mortality, necessitating advanced interventions.
Purpose of the Study:
- To review the pathophysiology and rationale for fetal lung recruitment therapies in CDH.
- To examine current prenatal diagnosis, risk stratification, and fetal intervention evidence.
- To discuss the impact of fetal therapy on postnatal care and emerging prenatal strategies.
Main Methods:
- Review of current literature on CDH pathophysiology and fetal interventions.
- Analysis of diagnostic and risk stratification advancements in prenatal imaging.
- Evaluation of evidence supporting fetoscopic endoluminal tracheal occlusion (FETO) and other fetal therapies.
Main Results:
- Prenatal imaging enables risk stratification for severe CDH.
- Fetoscopic endoluminal tracheal occlusion (FETO) has demonstrated improved survival in select cases.
- Uncertainty remains regarding optimal patient selection, timing, and generalizability of fetal therapies.
Conclusions:
- CDH should be viewed as a prenatal cardiopulmonary disease with postnatal surgical aspects.
- Fetal therapies offer a paradigm shift in managing severe CDH, improving lung development.
- Multidisciplinary counseling and perioperative planning are crucial in the era of fetal therapy.
More Related Videos
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.